14 C]-Serotonin release assay (14C-SRA) from platelets is considered to be the most sensitive test for laboratory confirmation of heparin-induced thrombocytopenia (HIT). This study compared 14C-SRA with an enzyme immunoassay (EIA) to determine the release of serotonin from platelets in the presence of heparin and serum from HIT patients. The normal range (median, 2´5 and 97´5 percentiles) of serotonin release from platelets in healthy subjects (n 149) is 38 ng/ml (19 and 62) measured by EIA-SRA. Serum from HIT patients (n 42) released 2548 ng/ml (244 and 7987) serotonin in the presence of 0´1 IU/ml heparin and 29 ng/ml (13 and 76) in the presence of 100 IU/ml heparin. One hundred per cent and 15% of HIT samples exhibited an elevated serotonin release from platelets in the presence of 0´1 IU/ml low molecular weight (LMW) heparin, 2100 ng/ml (869 and 5968), or danaparoid, 272 ng/ml (143 and 403), respectively. The sensitivity and specificity of the EIA-SRA was 100% and 97´4% and of the 14C-SRA 100% and 92´9% in HIT patients. No falsepositive results were found in patients receiving heparin (n 28), in patients with elevated levels of bilirubin (n 5), in patients with antiphospholipid antibody syndrome (n 10) or in non-HIT patients (n 78) with both assays. The EIA technique to quantify serotonin release from platelets provides a reliable non-radioactive method to diagnose heparin-induced thrombocytopenia and to assess in vitro crossreactivity of low molecular weight heparins and heparinoid.
During heparin therapy, heparin-induced thrombocytopenia (HIT) with or without thromboembolism may occur as a severe complication in 2±5% of patients (Chong, 1995) . HIT is caused by a neoantigen, which is expressed on platelet factor 4 (PF4) after binding to heparins and induces the production of antibodies, mostly of the IgG subclass (Greinacher et al, 1994a; Yporen et al, 1998) . Features or a falling platelet count mostly begin within 5±7 d after initiation of therapy and are variably accompanied by clinical symptoms . The diagnosis of HIT may be difficult on the basis of clinical symptoms alone, especially in patients with other diseases which may induce thrombocytopenia. Laboratory confirmation of HIT is therefore required.
Biological and antigen assays are available to confirm the diagnosis of HIT. Biological assays involve the [ 14 C]-serotonin release assay (Sheridan et al, 1986) , heparininduced platelet activation assay (Greinacher et al, 1991 (Greinacher et al, , 1994 and flow cytometric assay (Lee et al, 1996; Tomer,1997) . Antigen assays include the determination of the PF4/heparin complex by enzyme-linked immunosorbent assay (ELISA) (Amiral et al, 1992) and determination of heparin-induced IgG by biotin-labelled PF4 (Newman et al, 1998) and by fluorescent-labelled heparin (Wang et al, 1999a) . The [ serotonin from donor platelets in the presence of heparin, low molecular weight (LMW) heparin or danaparoid and serum from HIT patients. The assay was named EIA-SRA.
METHODS
Patients and samples. HIT was suspected in patients when the platelet count fell below 100 000 Â 10 9 /l or by . 50% of the pretreatment value and/or when thromboembolism occurred during heparin therapy. The diagnosis was confirmed according to the following criteria (Warkentin et al, 1998) : fall in platelet count to less than 100 Â 10 9 /l or by , 50% of the initial value and/or objectively documented thromboembolic complication during heparin therapy; recovery from thrombocytopenia after cessation of heparin; exclusion of other causes of thrombocytopenia. Based on these criteria, the diagnosis of HIT was confirmed in 42 of 120 suspected HIT patients between April 1997 and December 1998. Thirty-four patients received highdose unfractionated heparin (mean treatment period 14 d), four patients received high-dose unfractionated heparin followed by low-dose low molecular weight (LMW) heparin (mean 8 d) and four patients received low-dose LMW heparin (mean 5 d).
The [
14 C]-serotonin release assay (14C-SRA) and the EIA-SRA were compared in 312 samples. Five groups of patients were analysed: normal controls who had never had any of the above-mentioned criteria for HIT (n 149), HIT patients (n 42), non-HIT patients (n 78), patients on heparin treatment (n 28), patients with hyperbilirubinaemia (n 5) and patients with prolonged activated partial thromboplastin time (aPTT) and antiphospholipid syndrome (n 10). Blood was collected from all patients into plastic tubes containing kaolin and was centrifuged within 30 min at 1800 g for 20 min at room temperature. Serum was aliquoted, shock frozen in liquid nitrogen and stored at 2808C. The study was approved by the ethics committee of the University of Heidelberg and informed consent was obtained from each person.
14C-SRA. The 14C-SRA was performed as previously described (Sheridan et al, 1986) . Briefly, platelets were prepared from healthy subjects by collection of blood into acid citrate±dextrose solution (1:6, v/v). Platelet-rich plasma (PRP) was obtained by centrifugation within 10 min at 250 g and at room temperature for 15 min. The platelets were washed with calcium-and albumin-free Tyrode's buffer containing 2 units/ml apyrase (Sigma Aldrich, Deisenhofen, Germany) and 2 mg/ml r-hirudin (Hoechst Marion Roussel, Bad Soden, Germany), pH 6´2, and resuspended in calcium-and magnesium-containing albumin-free Tyrode's buffer, pH 7´4. The platelet count was adjusted to 300 Â 10 9 /l. The PRP was incubated with [ 14 C]-serotonin (Amersham Pharmacia Biotech, Freiburg, Germany) for 45 min at 378C (370 kBq [
14 C]-serotonin/ml of PRP). Serum (200 ml) was incubated at 568C for 30 min and was centrifuged at 1800 g for 20 min at 258C. Twenty microlitres of the middle layer, 75 ml of the platelet preparation and 5 ml of heparin solution (0´1 and 100 IU heparin final concentration; 160 IU/mg dry substance; Braun, Melsungen, Germany) were incubated for 1 h and at 258C with gentle mixing. Fifty microlitres of 27 mmol ethylene diamine tetra-acetic acid (EDTA; Sigma Aldrich) was added to terminate the reaction. Samples were centrifuged within 10 min at 1800 g and room temperature for 20 min and the radioactivity of 50 ml supernatant was measured in a scintillation counter (Beckman Instruments, Munich, Germany). The maximum release of [
14 C]-serotonin from platelets was obtained after lysis of platelets with 25 ml Triton X-100 (Sigma Aldrich). A positive result was defined as radioactivity above the 97´5 percentile of the median value of all subjects, i.e. 122 c.p.m. The same negative and positive controls were run in all experiments.
EIA-SRA. Platelets were prepared as for the 14C-SRA and were adjusted to a final concentration of 1500 Â 10 9 /l. The fivefold higher concentration of platelets was chosen because the serotonin concentration released from platelets in the presence of normal serum was below the lower limit of detection (LOD) at lower amounts (data not shown). Accordingly, the final concentrations of unfractionated heparin, LMW heparin (160 IU; dalteparin; Pharmacia & Upjohn, Germany) and danaparoid sodium (10 anti-factor Xa units/mg; Organon, Oss, Holland) were fivefold higher than in the 14C-SRA, i.e. 0´5 IU and 500 IU/ml for heparin and LMW heparin and 0´05 IU and 50 IU/ml for danaparoid. The established procedure was as follows, based on results from preliminary experiments (data not shown): 40 ml prepared serum, 5 ml of the anticoagulant (heparin, LMW heparin or danaparoid) and 75 ml platelet preparation were incubated for 60 min at room temperature with gentle mixing. The reaction was terminated by adding 100 ml of 27 mmol EDTA and samples were centrifuged within 10 min at 1800 g at room temperature for 15 min. The supernatant contained serotonin released from platelets and was quantified by a commercially available ELISA (IBL, Hamburg, Germany) (Hrycaj et al, 1996) . The assay was performed as follows: samples and serotonin standard dilutions were applied to microtitre plates coated with goat anti-rabbit antibody followed by 50 ml biotin-labelled serotonin and 50 ml rabbit serotonin antibody and were incubated overnight at 48C. After washing with PBS, 150 ml goat antibiotin antibody conjugated with alkaline phosphatase in Tris buffer was incubated for 2 h at room temperature with gentle mixing and was washed again. Para-nitrophenyl-phosphate was added and the reaction was terminated after 60 min by 50 ml of 1 m sodium hydroxide. The absorption was measured at 405 nm on the microtitre plate reader MR 7000 (Dynex, Denkendorf, Germany) and the concentration of serotonin was calculated from the reference curve using the biolinx 2´22 software program. The assay takes 24 h because of the overnight incubation time with the serotonin antibody. A positive result was defined as a concentration of serotonin above the 97´5 percentile of the median value of all subjects, i.e. 82 ng/ml. The same negative and positive controls were run in all experiments.
Statistical analysis. The non-parametric log-rank test was used to analyse statistically significant differences between the groups. Data are given as medians and 2´5 and 97´5 percentiles. The receiver operating characteristic (ROC) curve was calculated for the 14C-and EIA-SRA (Metz, 1978) .
RESULTS
The lower limit of detection of the EIA-SRA was 16 ng/ml determined from the upper limit of the mean and threefold standard deviation of a buffer control not containing serotonin (n 15, assays performed on different days). The quantity of serotonin released from platelets in the presence of serum and no heparin ranged from 16 to 86 ng/ml. The intra-assay (n 20) and interassay (n 15) coefficients of variation of normal and HIT samples were between 8% and 13%.
The 14C-and EIA-SRA were positive in 39/42 and 42/42 of samples from clinically verified HIT patients. The serotonin concentration (median and 2´5 and 97´5 percentiles) was 35 ng/ml (21 and 81 ng/ml) in the absence of heparin and 2548 ng/ml (244 and 7987 ng/ml) in the presence of 0´1 IU heparin/300 Â 10 9 platelets/l (P , 0´00001). In the presence of 100 IU/ml, the serotonin concentration was 28 ng/ml (14 and 76 ng/ml) in HIT patients (Fig 1) .
The 14C-and EIA-SRA were negative in 78/78 and 76/78 non-HIT patients respectively. The concentration of serotonin (EIA) was 39 ng/ml (22 and 82 ng/ml) in the absence of heparin and 42 ng/ml (18 and 101 ng/ml) in the presence of 0´1 IU heparin (P 0´08). Both assays were negative in 149/149 control patients. The serotonin concentrations as determined by the EIA were 38 ng/ml (19 and 62 ng/ml) in the absence of heparin and 38 ng/ml (16 and 64 ng/ml) in the presence of 0´1 IU heparin (P 0´31). Both assays were negative in 28/28 patients receiving heparin. The serotonin concentration was 39 ng/ml (27 and 58 ng/ml) in the absence and 39 ng/ml (26 and 71 ng/ml) in the presence of 0´1 IU heparin (P 0´28) in patients during high-dose heparin therapy (n 28). In patients with antiphospholipid syndrome (n 10), both assays were negative with serotonin concentrations of 40 ng/ml (24 and 70 ng/ml) in the absence and 36 ng/ml (27 and 85 ng/ml) in the presence of 0´1 IU heparin (P 0´31). In patients with hyperbilirubinaemia (n 5), the 14C-and EIA-SRA were both negative. The concentration of serotonin was 43 ng/ml (35 and 65 ng/ml) in the absence and 42 ng/ml (31 and 75 ng/ml) in the presence of 0´1 IU heparin (EIA, P 0´33). Data are shown as medians with 2´5 and 97´5 percentiles in Fig 1. All HIT sera with a high release of serotonin in the presence of 0´1 IU heparin showed a high release of serotonin from donor platelets with LMW heparin also, as follows: 24 ng/ml (18 and 31 ng/ml) without and 2100 ng/ml (922 and 5968 ng/ml) with 0´1 IU (P , 0´00001) and 20 ng/ml (11 and 67 ng/ml) with 100 IU LMW heparin. Four of these patients had an elevated release of serotonin with 0´01 IU danaparoid, as follows: 40 ng/ml (24 and 67 ng/ml) without and 272 ng/ml (143±403 ng/ml) with 0´01 IU (number too small for statistical analysis) and 44 ng/ml (34 and 74 ng/ml) with 10 IU danaparoid/ml.
The sensitivity and specificity of the EIA-SRA was compared with the 14C-SRA and was calculated from all the samples. The results are given in Table I . The sensitivity and specificity of the EIA-SRA were 100% and 98´2%, respectively, compared with the 14C-assay. Of the five patients with positive results in the EIA-SRA and negative results in the 14C-SRA, three were false negatives by the 14 C assay relative to the clinical diagnosis. Patients developed a fall in platelets of . 50% of the pretreatment values 7±10 d after initiation of heparin therapy and venous thrombosis (n 2) or myocardial infarction (n 1). Platelet count normalized within 5 d in the patients after switching anticoagulation to intravenous r-hirudin (Hoechst Marion Roussel) with the aim of a 1´5-to twofold prolongation of the aPTT. Two non-HIT patients were false positives in the EIA-SRA. HIT was suspected because of a fall in the platelet count to . 50% of the value before the start of heparin therapy. They did not exhibit a thromboembolic Medians (±) and 2´5 and 97´5 percentiles of the serotonin concentration released from donor platelets after incubation with serum from (1) HIT patients (n 27), (2) non-HIT patients (n 76), (3) control subjects (n 149), (4) patients during heparin therapy (n 28), (5) patients with antiphospholipid syndrome (n 10) and (6) hyperbilirubinaemia (n 5) in the presence of saline (shaded columns) or 0´1 IU heparin/ml (final concentration per 300 000 platelets, open columns). Table I . Comparison of the results of serotonin release from donor platelets in the presence of serum (42 HIT patients, 268 samples from patients without HIT) and 0´1 IU heparin/ml using EIA-and 14C-SRA. The sensitivity and specificity of the EIA-SRA was 100% and 98´2% compared with the 14C-SRA. Positive  39  0  39  Negative  5  208  273  Total  44  268  312 complication and prophylaxis of thromboembolism was switched to 2 Â 25 mg r-hirudin subcutaneously. The platelet count did not increase after cessation of heparin and no thromboembolic complications occurred. One patient was on chemotherapy and remained thrombocytopenic (120 Â 10 9 /l) and the other patient suffered from septicaemia. Both were returned to LMW heparin therapy after exclusion of HIT without a decrease in the platelet count.
The ROC curves were calculated for the 14C-and EIA-SRA. The area under the ROC curve for the EIA-SRA was 0´999 and for the 14-SRA 0´967. As seen from Fig 2, a cutoff value of 120 ng serotonin/ml yielded 100% specificity and 97´4% sensitivity for the EIA-SRA. Figure 3 shows 100% sensitivity for the 14C-SRA at 63´5 c.p.m. and 58% specificity. At a cut-off value of 100 c.p.m., the sensitivity of the 14 C assay was 92% and the specificity 98´2% compared with the clinical diagnosis.
DISCUSSION
Heparin-induced thrombocytopenia is one of the major severe complications of heparin treatment. The [ 14 C]-serotonin release assay has been demonstrated to have the highest sensitivity and specificity of the available assays (Warkentin et al, 1998) . The disadvantage of the assay relates to the use of radioactivity. In the present paper, we describe the determination of serotonin from platelets using an EIA technique. The results demonstrate a . 95% specificity and sensitivity compared with the 14C-SRA and the HIT diagnosis. The method is based on the measurement of serotonin from donor platelets in the presence of serum from HIT patients and a low heparin concentration. The main difference from the [ 14 C]-serotonin assay was that platelets were not preincubated with serotonin (Sheridan et al, 1986) . The quantitative determination of serotonin release from the dense granules of platelets may be of importance for interaction studies with other glycosaminoglycans for the follow-up of patients.
As described previously (Sheridan et al, 1986) , the release of serotonin is induced in the presence of low concentrations of heparin, low molecular weight heparin and danaparoid and is inhibited in the presence of high concentrations of the anticoagulants. This was also found in the present study when measuring the concentration of serotonin by EIA. The ROC curve of the EIA-SRA demonstrated that the assay was sensitive in 100% of samples and specific in 98´2% at a cutoff of 120 ng serotonin/ml for the diagnosis of HIT. The areas under the ROC curve of the EIA-and the 14C-SRA were similar (0´999 and 0´967 respectively) and underlined the accuracy of the EIA. The EIA-SRA showed positive results in all patients with the clinical diagnosis of HIT and two positive results in non-HIT patients compared with the 14C-SRA. Three HIT patients were identified by the EIA but not by the 14 C assay. The sensitivity and specificity of the 14C-SRA in the present study were similar to the data reported in the literature (Sheridan et al, 1986; Kelton et al, 1988; Arepally et al, 1995) . This underlines the validity of the present data obtained with the EIA method to determine the release of serotonin from platelets in the presence of HIT serum.
The EIA used a serotonin standard to quantify the release of serotonin. Thus, a quantification of the immunological process of HIT may become possible. As shown from the results using danaparoid as the anticoagulant in the assay, less serotonin was released from platelets in the presence of HIT serum than with heparin and LMW heparin. Whether this finding can also explain the lower incidence of HIT in danaparoid-treated patients remains to be studied in a larger series of experiments (Magnani, 1993) . To date, the lower incidence of HIT in these patients has been attributed to the difference in the chemical structure of danaparoid and the heparins (Magnani, 1993; Greinacher et al, 1994; Chong, 1995) and a lower incidence of the binding of danaparoid to HIT-IgG in the presence of platelet factor 4 (Wang et al, 1999b) . The present data support the literature findings whereby LMW heparins crossreact with HIT antibodies in 100% of patients. The absolute release of serotonin from platelets was not different in the presence of LMW heparin from that in the presence of unfractionated heparin. This further supports the assumption that the immunological interaction of LMW heparin is different and Fig 2. ROC curve of the EIA-SRA. The area under the curve was 0´999. The inset shows an enlarged x-axis to visualize the specificity of the assay. is almost 100% in the presence of platelets, in contrast to a lower rate of interaction with HIT serum in the absence of platelets (Wang et al, 1999a) .
In conclusion, the present study demonstrated that the release of serotonin from platelets is sensitively and specifically measured by an EIA technique. The advantage over the [ 14 C]-serotonin assay is the avoidance of radioactivity and the quantitative determination of serotonin. This offers the possibility of standardizing laboratory methods and of following up the disease in HIT patients.
